Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3339-3349

  Black, Michael T ^a   Stachyra, Thérèse ^a   Platel, Denis ^a   Girard, Anne Marie ^a   Claudon, Monique ^a   Bruneau, Jean Michel ^a   Miossec, Christine ^a  

^a Novexel SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; MOXIFLOXACIN; NXL 101; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; BACTERIUM MUTANT; DRUG INHIBITION; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ESCHERICHIA COLI; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ENGINEERING; GENETIC VARIABILITY; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; ESCHERICHIA COLI; FLUOROQUINOLONES; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; POINT MUTATION; QUINOLINES; STAPHYLOCOCCUS AUREUS;

EID: 50949110901     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00496-08     Document Type: Article

References (36)

1. Alovero, F. L., X.-S. Pan, J. E. Morris, R. H. Manzo, and L. M. Fisher. 2000. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob. Agents Chemother. 44:320-325.
2. Anderson, V. E., R. P. Zaniewski, F. S. Kaczmarek, T. D. Gootz, and N. Osheroff. 2000. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement. Biochemistry 39:2726-2732.
3. Bates, A. D., and A. Maxwell. 2005. DNA topology. Oxford University Press, Oxford, United Kingdom.
4. Bates, A. D., and A. Maxwell. 2007. Energy coupling in type II topoisomerases: why do they hydrolyze ATP? Biochemistry 46:7929-7941.
5. Blanche, F., B. Cameron, F. X. Bernard, L. Maton, B. Manse, L. Ferrero, N. Ratet, C. Lecoq, A. Goniot, D. Bisch, and J. Crouzet. 1996. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother. 40:2714-2720.
6. Champoux, J. J. 2001. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70:369-413.
7. Corbett, K. D., and J. M. Berger. 2004. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct. 33:95-118.
8. Corbett, K. D., A. J. Schoeffler, N. D. Thomsen, and J. M. Berger. 2005. The structural basis for substrate specificity in DNA topoisomerase IV. J. Mol. Biol. 351:545-561.
9. Corbett, K. D., R. K. Shultzaberger, and J. M. Berger. 2004. The C-terminal domain of DNA gyrase A adopts a DNA-bending beta-pinwheel fold. Proc. Natl. Acad. Sci. USA 101:7293-7298.
10. Drlica, K., M. Malik, R. J. Kerns, and X. Zhao. 2008. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52:385-392.
11. Fisher, L. M., K. A. Gould, X.-S. Pan, S. Patel, and V. J. Heaton. 2003. Analysis of dual active fluoroquinolones in Streptococcus pneumoniae. J. Antimicrob. Chemother. 52:312-313.
12. Forterre, P., S. Gribaldo, D. Gadelle, and M. C. Serre. 2007. Origin and evolution of DNA topoisomerases. Biochimie 89:427-446.
13. Friedman, S. M., T. Lu, and K. Drlica. 2001. Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob. Agents Chemother. 45:2378-2380.
14. Heaton, V. J., J. E. Ambler, and L. M. Fisher. 2000. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob. Agents. Chemother. 44:3112-3117.
15. Hockings, S. C., and A. Maxwell. 2002. Identification of four GyrA residues involved in the DNA breakage-reunion reaction of DNA gyrase. J. Mol. Biol. 318:351-359.
16. Hooper, D. C. 2001. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 32(Suppl. 1):S9-S15.
17. Horowitz, D. S., and J. C. Wang. 1987. Mapping the active site tyrosine of Escherichia coli DNA gyrase. J. Biol. Chem. 262:5339-5344.
18. Ince, D., X. Zhang, and D. C. Hooper. 2003. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1410-1415.
19. Ince, D., X. Zhang, L. C. Silver, and D. C. Hooper. 2003. Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:274-282.
20. Ince, D., X. Zhang, L. C. Silver, and D. C. Hooper. 2002. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob. Agents Chemother. 46:3370-3380.
21. Laponogov, I., D. A. Veselkov, M. K. Sohi, X.-S. Pan, A. Achari, C. Yang, J. D. Ferrara, L. M. Fisher, and M. R. Sanderson. 2007. Breakage-reunion domain of Streptococcus pneumoniae topoisomerase IV: crystal structure of a gram-positive quinolone target. PLoS ONE 2:e301.
22. Levasseur, P., A.-M. Girard, and J. Lowther. 2007. Efficacy of oral NXL101, a novel topoisomerase inhibitor, against fluoroquinolone- susceptible (FQS) and -resistant (FQR) Streptococcus pneumoniae (Sp) strains in a mouse pneumonia model, abstr. F1-2125, p. 260. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
23. Levasseur, P., C. Delachaume, J. Lowther, and J. Hodgson. 2005. Minimum inhibitory concentrations (MIC) and mutation prevention concentrations (MPC) of NXL101, a novel topoisomerase IV inhibitor, against Staphylococcus aureus including multi-resistant strains, abstr. F-507, p. 184. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother.
24. Lowther, J., P. Levasseur, A.-M. Girard, C. Delachaume, M. Borgonovi, and J. Hodgson. 2006. Efficacy of NXL101, a novel topoisomerase inhibitor, against multi-resistant Staphylococcus aureus in murine septicaemia and thigh muscle infections, abstr. F1-1999, p. 239. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother.
25. Malik, M., X. Zhao, and K. Drlica. 2006. Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol. Microbiol. 61:810-825.
26. Morais Cabral, J. H., A. P. Jackson, C. V. Smith, N. Shikotra, A. Maxwell, and R. C. Liddington. 1997. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388:903-906.
27. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
28. Pan, X.-S., P. J. Hamlyn, R. Talens-Visconti, F. L. Alovero, R. H. Manzo, and L. M. Fisher. 2002. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones. Antimicrob. Agents Chemother. 46:2498-2506.
29. Pestova, E., J. J. Millichap, G. A. Noskin, and L. R. Peterson. 2000. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother. 45:583-590.
30. Schmitz, F.-J., B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, M. Klootwijk, J. Verhoef, A. Fluit, H.-P. Heinz, K. Kohrer, and M. E. Jones. 1998. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 41:481-484.
31. Sheehan, G., and N. S. Y. Chew. 2003. The history of quinolones, p. 1-10. In A. R. Ronald and D. E. Low (ed.), Fluoroquinolone antibiotics. Birkhäuser Verlag, Basel, Switzerland.
32. Strahilevitz, J., A. Robicsek, and D. C. Hooper. 2006. Role of the extended α4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones. Antimicrob. Agents Chemother. 50:600-606.
33. Strahilevitz, J., Y. Onodera, and D. C. Hooper. 2006. An improved expression plasmid for affinity purification of Staphylococcus aureus gyrase A subunit. Protein Expr. Purif. 47:10-15.
34. Tarral, A., M. Rangaraju, H. Merdjan, A.-M. Girard, C. Delachaume, and J. Lowther. 2007. Plasma bactericidal activity of NXL101 in healthy volunteers after single intravenous administrations of 50 mg to 700 mg, abstr. A-808, p. 25. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
35. Truong, Q. C., J.-C. van Nguyen, D. Shlaes, L. Gutmann, and N. J. Moreau. 1997. A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics. Antimicrob. Agents Chemother. 41:85-90.
36. Yague, G., J. E. Morris, X.-S. Pan, K. A. Gould, and L. M. Fisher. 2002. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob. Agents Chemother. 46:413-419.